QNRX צמיחת רווח למניה השנה Quoin Pharmaceuticals

A comparison of annual EPS growth demonstrates profit dynamics, where the value 65.40 captures this metric. Quoin Pharmaceuticals (QNRX) relies on a compact staff of elite dermatologists with full core loyalty. The business model is based on the complete outsourcing of production and clinics to external partners. The development of drugs for rare skin pathologies ensures stable demand and long repeat sales cycles.
פילוחי מדדים פיננסיים ומדדי שוק עבור Quoin Pharmaceuticals (QNRX)

For Quoin Pharmaceuticals (QNRX), whose market capitalization depends on the success of Netherton syndrome therapy, the year-over-year earnings per share dynamics serve as an indicator of the effectiveness of commercializing its developments. This metric measures the percentage deviation of the current EPS from the same figure last year, revealing the growth or stagnation rates of net income. A positive trend on the chart confirms the biotech startup's transition to a phase of sustainable profitability.